Alembic gets USFDA nod for generic Retin-A — but market is small
The $76 million US market for Tretinoin Cream is less than 1% of Alembic's annual revenue, making this a routine pipeline addition.
— 6 earlier stories on Alembic Pharmaceuticals Ltd. →What's new
- USFDA granted final approval for generic Tretinoin Cream 0.05%, a copy of Retin-A.
- Addressable US market is $76 million, less than 1% of Alembic's ₹7,345 cr revenue.
- Approval adds to the company's 242 ANDA pipeline but is below materiality threshold.
Why this matters
For a mid-cap pharma with a ₹14,581 cr market cap, a $76 million market is a rounding error. Routine approvals like this keep the pipeline fresh but don't shift earnings expectations. Alembic's recent 180-day exclusivity win on Larotrectinib was far more consequential.
What we're watching
- Timeline for commercial launch and potential market share capture.
- Next major USFDA action on higher-value pipeline products.
- Any update on the Canadian JV or Larotrectinib exclusivity launch.
The full read
Alembic Pharmaceuticals picked up another USFDA final approval, this time for generic Tretinoin Cream 0.05%, a copy of Retin-A. The US market is $76 million. For a company with trailing revenue of ₹7,345 crore, that is less than 1% of sales. It won't move the needle. This is a routine addition to a pipeline that already counts 242 ANDA approvals. It is genuinely new but not quantitatively significant. Alembic's more consequential recent wins, like the $91 million Larotrectinib approval with 180-day exclusivity, are what merit attention.
Questions answered
- How big is the Tretinoin Cream market relative to Alembic's revenue?
- The $76 million US market is less than 1% of Alembic's trailing revenue of ₹7,345 crore, making it immaterial for earnings.
- Is this approval a surprise or expected?
- Final approvals are routine for Alembic, which already has 242 ANDA approvals. The event is genuinely new but not unexpected given the pipeline.
- Does this approval open up any exclusivity period?
- No 180-day exclusivity or first-to-file status was mentioned. This is a standard generic approval.
- How does this compare to Alembic's other recent USFDA wins?
- Alembic's earlier Larotrectinib approval had a $91 million market and included 180-day exclusivity, making it far more significant than this Tretinoin approval.
Alembic Pharmaceuticals Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on APLLTD →- 12 Jun 2026 · 12:47 PM IST Alembic gets USFDA nod for generic Retin-A — but market is small
- today Alembic eyes $259M cancer market with tentative US nod for Binimetinib
- 8d ago Alembic lands 180-day exclusivity shot on $91m US cancer drug
- 13d ago Alembic takes 45% in new Canadian pharma JV with Difgen Holdings
- 14d ago Alembic lands generic Haldol approval, but the US market is tiny